Story thread · 15 reports / 12 sources

Novartis CAR-T deaths raise questions over acceptable autoimmune risk

endpts.com · 12dShare

Many researchers believe cancer cell therapies called CAR-Ts could shift the treatment paradigm for patients with autoimmune disease. But three recently disclosed deaths in Novartis’ clinical trials serve as a stark reminder that the modality ...

First report: Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns — biopharmadive.com, 14d